Alessandro C.
- Country
- Germany
- Department
- St. Marien-Krankenhaus - Klinikum Westmünsterland GmbH
Research Overview
- A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS]
- SGLT2 INHIBITION FOR CARDIOVASCULAR ENDPOINT REDUCTION IN HYPERTENSION
- ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Data & Insights
Has run more than one trial at 36 of 501 partner sites.
Specializations
Calcific aortic valve stenosis and lipoprotein(a)-related cardiovascular disease
Alessandro Cuneo is involved in clinical research focused on calcific aortic valve stenosis, with particular attention to disease progression linked to lipoprotein(a) lowering and valvular calcification.
- Peak aortic jet velocity
- Aortic valve calcium score
- Cardiac valve disease
This area reflects an interest in therapies aimed at slowing structural heart valve deterioration and modifying cardiovascular risk associated with calcific valve disease.
Hypertension management
His clinical trial activity includes arterial hypertension and hypertension, with emphasis on treatment strategies for patients whose blood pressure remains insufficiently controlled.
- Blood pressure control
- Antihypertensive therapy
- Treatment-resistant hypertension
The therapeutic focus extends to approaches intended to improve long-term cardiovascular outcomes through better control of elevated blood pressure.
SGLT2 inhibitor-based cardiovascular and renal protection
He is also engaged in research evaluating sodium-glucose co-transporter 2 inhibitors as add-on treatment in hypertension, with interest in reducing combined cardiovascular and renal events.
- Major adverse cardiovascular events
- Renal protection
- Cardiometabolic risk reduction
This domain connects blood pressure treatment with prevention of complications affecting both the heart and kidneys.
Cardiovascular risk reduction in high-risk patients
His research landscape includes patients with established cardiovascular disease and those at high cardiovascular risk, with attention to therapies designed to prevent major events such as myocardial infarction, stroke, and heart failure.
- Cardiovascular death
- Nonfatal myocardial infarction
- Heart failure events
This area underscores involvement in preventive cardiovascular medicine for patients with advanced risk profiles.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.